Quill Science LLC’s Post

View organization page for Quill Science LLC, graphic

238 followers

Our inaugural issue of The Quill Quartet is here! Four things you might have missed in immunology/rheumatology from the past couple of months. Read more: ▪️Circulating regulatory T cells: https://buff.ly/4f9Qc1i ▪️Digital health in rheumatoid arthritis (RA): https://buff.ly/3W8tgXq ▪️Tyenne approved by the FDA: https://buff.ly/3Wr3Kht ▪️ Long-term safety and efficacy of CAR-T cell treatment in severe and treatment refractory autoimmune disease: https://buff.ly/4fb2LZY More about the CAR-T study: In data presented at EULAR 2024, patients with refractory lupus (SLE n=8), systemic sclerosis (SSc, n=4), and idiopathic inflammatory myositis (IIM=3) were treated with experimental CD19-targeting CAR T cell therapy. At ≥1 year after treatment (median follow-up of 18 months), all 15 patients had stopped immunosuppressive therapy. All patients achieved remission as defined by DORIS remission (SLE), all IIM patients reached ACR/EULAR major response (IIM) and improvement in the EUSTAR activity index (SSc).

We're excited to launch this biweekly newsletter. Let us know what you think so we can deliver what matters!

Like
Reply

To view or add a comment, sign in

Explore topics